Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background: Oral cancer radical surgery often requires free flap reconstruction. Postoperative pain is severe, and traditional opioids like sufentanil have side effects and may adversely affect tumor biology. Dezocine and nalbuphine are opioid agonist-antagonists with potentially better safety profiles. Their comparative effects on analgesia, complications, and flap survival in oral cancer surgery are unknown.
Objective: To compare the efficacy of dezocine versus nalbuphine, both combined with sufentanil, for postoperative analgesia, and to evaluate their impact on postoperative complications and free flap survival/function in patients undergoing oral cancer radical surgery with flap reconstruction.
Methods: This is a prospective, randomized, double-blind, controlled trial. Sixty eligible patients (aged 18-70, ASA I-III) will be randomly assigned (1:1) to receive postoperative patient-controlled intravenous analgesia (PCIA) with either Sufentanil + Dezocine or Sufentanil + Nalbuphine. The primary outcome is pain intensity assessed by the Visual Analogue Scale (VAS) at 2, 24, and 48 hours postoperatively. Secondary outcomes include flap survival status, sensory function recovery, incidence of adverse events (e.g., nausea, vomiting), and hospitalization duration.
Potential Impact: This study may identify a superior postoperative analgesic regimen that provides effective pain relief while potentially improving flap outcomes and minimizing side effects for oral cancer patients.
Design: Single-center, prospective, randomized, double-blind, active-controlled, parallel-group trial.
Interventions:
Group D: Sufentanil (1.0 µg/kg) + Dezocine (0.4 mg/kg) diluted to 150ml with normal saline for PCIA (no basal infusion, bolus 2.5 ml, lockout 15 min).
Group N: Sufentanil (1.0 µg/kg) + Nalbuphine (1.0 mg/kg) diluted to 150ml with normal saline for PCIA (parameters identical to Group D).
Standardized general anesthesia protocol for both groups.
Primary Outcome: Postoperative pain scores (VAS, 0-10) at rest at 2, 24, and 48 hours after surgery.
Secondary Outcomes:
Flap survival status (e.g., hematoma, dehiscence, necrosis, infection) on postoperative days 1-7.
Flap sensory function: static/dynamic two-point discrimination and Semmes-Weinstein monofilament test on days 1-7.
Incidence of postoperative adverse events (nausea, vomiting, pruritus, dizziness, sedation).
Postoperative hospital stay duration.
Ramsay sedation scores at 2, 24, and 48 hours.
Intraoperative hemodynamics and blood loss.
Sample Size: 60 patients (30 per group). The calculation is based on a pilot study detecting a difference in 24h VAS scores (1.52 vs 2.35, SD=0.89) with 90% power and α=0.05, accounting for a 20% dropout rate.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dezocine + Sufentanil | Experimental | Participants in this arm receive postoperative patient-controlled intravenous analgesia (PCIA) with a mixture of Sufentanil (1.0 µg/kg) and Dezocine (0.4 mg/kg), diluted to a total volume of 150 ml with normal saline. The PCIA pump is set with no basal infusion, a bolus dose of 2.5 ml, a lockout interval of 15 minutes, and a maximum hourly limit of 15 ml. This intervention begins at the end of surgery. |
|
| Nalbuphine + Sufentani | Active Comparator | Participants in this arm receive postoperative patient-controlled intravenous analgesia (PCIA) with a mixture of Sufentanil (1.0 µg/kg) and Nalbuphine (1.0 mg/kg), diluted to a total volume of 150 ml with normal saline. The PCIA pump settings are identical to the experimental group: no basal infusion, a bolus dose of 2.5 ml, a lockout interval of 15 minutes, and a maximum hourly limit of 15 ml. This intervention begins at the end of surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dezocine and Sufentanil combination | Drug | Postoperative patient-controlled intravenous analgesia (PCIA) regimen. The intervention consists of a mixture of two drugs: Sufentanil (at a dose of 1.0 µg per kg of body weight) and Dezocine (at a dose of 0.4 mg per kg). This combination is diluted with normal saline to a total volume of 150 ml and administered via a PCIA pump. The pump is programmed with no background infusion, a patient-controlled bolus of 2.5 ml, a lockout interval of 15 minutes, and a maximum hourly limit of 15 ml. The infusion begins at the end of surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative Pain Intensity | Pain intensity assessed at rest using the Visual Analogue Scale (VAS). The VAS is a 100-mm horizontal line where 0 mm represents "no pain" and 100 mm represents "the worst pain imaginable." Patients mark their current pain level on the line. | At 2 hours, 24 hours, and 48 hours after surgery. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Flap Complications | The occurrence of complications in the transferred free flap, assessed daily by clinical examination. Complications include hematoma, wound dehiscence, skin necrosis, and infection. | Daily from postoperative day 1 to day 7. |
| Flap Sensory Recovery - Two-Point Discrimination (2PD) |
| Measure | Description | Time Frame |
|---|---|---|
| Flap Sensory Recovery - Pain Perception | Sensory function recovery of the flap assessed specifically for pain perception threshold. This is measured using an algesimeter, a device that applies a standardized, gradually increasing mechanical stimulus (e.g., pressure in grams or Newtons) to the flap surface until the patient first reports a sensation of pain. The threshold value (e.g., in grams) is recorded. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ganglan Fu, M.D. | Contact | 86+13570275074 | ganglan@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Anesthesiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen Universit | Recruiting | Guangzhou | Guangdong | 510000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Nalbuphine and Sufentanil combination | Drug | Postoperative patient-controlled intravenous analgesia (PCIA) regimen. The intervention consists of a mixture of two drugs: Sufentanil (at a dose of 1.0 µg per kg of body weight) and Nalbuphine (at a dose of 1.0 mg per kg). This combination is diluted with normal saline to a total volume of 150 ml and administered via a PCIA pump. The pump settings are identical to the comparator regimen: no background infusion, a patient-controlled bolus of 2.5 ml, a lockout interval of 15 minutes, and a maximum hourly limit of 15 ml. The infusion begins at the end of surgery. |
|
Sensory function recovery of the flap assessed using a Disk-Criminator to measure static and dynamic two-point discrimination (2PD). Lower values indicate better sensory discrimination. |
| Daily from postoperative day 1 to day 7. |
| Flap Sensory Recovery - Light Touch Threshold | Sensory function recovery of the flap assessed using Semmes-Weinstein monofilaments. The test determines the minimal force (g/mm²) required for the patient to perceive light touch, with lower values indicating better sensitivity. | Daily from postoperative day 1 to day 7. |
| Incidence of Postoperative Adverse Events | The frequency of common postoperative adverse effects, including nausea, vomiting, pruritus (itching), dizziness, and somnolence (drowsiness), as recorded in patient charts and through direct questioning. | From the end of surgery until 48 hours postoperatively. |
| Ramsay Sedation Score | Level of sedation assessed using the Ramsay Sedation Scale (scores 1-6, where 1=anxious/agitated, 2=cooperative/oriented/tranquil, 3=responsive to commands only, 4-6=asleep with varying responses to stimulus). | At 2 hours, 24 hours, and 48 hours after surgery. |
| Postoperative Hospital Stay Duration | The total length of hospitalization (in days) from the day of surgery until the day of discharge, meeting standard discharge criteria. | From the day of surgery until the day of discharge (assessed up to 30 days). |
| Intraoperative Hemodynamic Stability | Measurement of intraoperative stability, including heart rate (beats per minute), blood pressure (mmHg), and peripheral oxygen saturation (SpO2, %). Data points are recorded every 5 minutes. | From anesthesia induction until the end of surgery (intraoperative period). |
| Daily from postoperative day 1 to day 7. |
| Long-term Flap Survival Rate | The viability of the free flap assessed clinically. Flap survival is defined as a viable, perfused flap without the need for emergency reoperation due to total necrosis. The outcome is reported as the percentage of patients with a fully surviving flap at each follow-up time point. | At 1 month, 6 months, and 1 year after surgery. |
| One-year Disease-free Survival | The proportion of patients alive without evidence of cancer recurrence (local, regional, or distant) at 1 year after surgery. | At 1 year after surgery. |
| Flap Sensory Recovery - Temperature Sensation | Sensory function recovery of the flap assessed specifically for temperature discrimination. This is measured using the Thissen temperature sensitivity test or similar calibrated thermodes. The test evaluates the ability to distinguish between warm and cold stimuli applied to the flap surface, typically reported as correct identification rates or threshold temperature differences | Daily from postoperative day 1 to day 7. |
| Flap Contour and Aesthetic Outcome | The aesthetic and contour outcome of the reconstructed site is assessed by a surgeon using a standardized visual analog scale (VAS). The assessor rates overall appearance, symmetry, and contour integration with surrounding tissues on a scale from 0 (very poor) to 10 (excellent). The mean VAS score at each time point will be reported. | At 1 month, 6 months, and 1 year after surgery. |
| Oromandibular Functional Recovery | Functional recovery related to the flap reconstruction is assessed using a patient-reported outcome measure (PROM) focusing on speech and swallowing. | At 1 month, 6 months, and 1 year after surgery. |
| ID | Term |
|---|---|
| D009062 | Mouth Neoplasms |
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D009059 | Mouth Diseases |
| D009057 | Stomatognathic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C010827 | dezocine |
| D009266 | Nalbuphine |
| ID | Term |
|---|---|
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
Not provided
Not provided